Initial results from a Phase 1/2 study of BT7480, a novel Nectin-4/CD137 Bicycle tumor-targeted immune cell agonist®, in patients with advanced solid tumors

We use cookies and other technologies to optimise your experience and analyse our traffic. Please confirm you are happy to accept. You can change your preferences in “Cookie Settings”.